This study is in progress, not accepting new patients

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

a study on Pancreatic Cancer Colorectal Cancer Breast Cancer Lung Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Santa Monica, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated.

This study will also provide another mechanism for reporting adverse events related to study drug safety.

Official Title

An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Keywords

Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer, Solid tumors, ruxolitinib, regorafenib, capecitabine, Ruxolitinib plus background cancer therapy, Background cancer therapy alone

Eligibility

You can join if…

Open to people ages 18 years and up

  • Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
  • Currently tolerating treatment in the parent protocol.
  • Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
  • Have at least stable disease, as determined by the investigator.
  • Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.

You CAN'T join if...

  • Has been permanently discontinued from study treatment in the parent study for any reason.
  • Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.

Locations

  • UCLA Healthcare Hematology-Oncology
    Santa Monica California 90404 United States
  • Renovatio Clinical Consultants Llc
    The Woodlands Texas 77380 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Incyte Corporation
ID
NCT02955940
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 10 people participating
Last Updated